Research paper

Cdh1-mediated Skp2 degradation by dioscin reprogrammes aerobic glycolysis and inhibits colorectal cancer cells growth

Li Zhoua,*,1, Xinfang Yub,1, Ming Lic,d,1, Guanghui Gonga, Wenbin Liue, Tian Li,†, Huilan Zouf, Wei Li,*,†, Feng Gaof,*, Haidan Liuh,i,*

Department of Pathology, Xiangya Hospital of Central South University, Changsha, Hunan 410008, PR China
b Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
c School of Stomatology, Hunan University of Chinese Medicine, Changsha, Hunan, 410028, PR China
d Department of Pathology, Hunan Cancer Hospital, Changsha, Hunan 410013, PR China
e Department of Ultrasoundography, The Third Xiangya Hospital of Central South University, Changsha, Hunan, 410013, PR China
f Department of Radiology, The Third Xiangya Hospital of Central South University, Changsha, Hunan, 410013, PR China
g Department of Cardiovascular Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, PR China
h Clinical Center for Gene Diagnosis and Therapy, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, PR China
i Department of Pathology, Xiangya Hospital of Central South University, Changsha, Hunan 410008, PR China
j Changsha Stomatological Hospital, Changsha, Hunan 410004, PR China
k Department of Pathology, The Clinical Center, Changsha, Hunan 410008, PR China
l Department of Pathology, The Clinical Center, Changsha, Hunan 410008, PR China
m Fourth Xiangya Hospital of Central South University, Changsha, Hunan 410008, PR China

ABSTRACT

Background: The F-box protein S-phase kinase-associated protein 2 (Skp2) is overexpressed and correlated with poor prognosis in human malignancies, including colorectal cancer (CRC).

Methods: A natural product library was used for natural compound screening through glycolysis analysis. The expression of Skp2 in CRCs and the inhibitory effect of dioscin on glycolysis were examined through methods of immunoblot, immunofluorescence, immunohistochemical staining, anchorage-dependent and -independent growth assays, EdU incorporation assay, ubiquitination analysis, co-immunoprecipitation assay, CRISPR-Cas9-based gene knockout, and xenograft experiment.

Findings: We demonstrated that Skp2 was highly expressed in CRC tissues and cell lines. Knockout of Skp2 inhibited HK2 and glycolysis and decreased CRC cell growth in vitro and in vivo. We screened 88 commercially available natural products and found that dioscin, a natural steroid saponin derived from several plants, significantly inhibited glycolysis in CRC cells. Dioscin decreased the protein level of Skp2 by shortening the half-life of Skp2. Further study showed that dioscin attenuated Skp2 phosphorylation on S72 and promoted the interaction between Skp2 and Cdh1, which eventually enhanced Skp2 lysine 48 (K48)-linked polyubiquitination and degradation. Depletion of Cdh1 impaired dioscin-induced Skp2 reduction, rescued HK2 expression, and glycolysis in CRC cells. Finally, dioscin delayed the in vivo tumor growth, promoted Skp2 ubiquitination, and inhibited Skp2 expression in a mouse xenograft model.

Interpretation: This study suggests that in addition to pharmacological inactivation of Skp2, enhancement of ubiquitination-dependent Skp2 turnover is a promising approach for cancer treatment.

© 2019 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)

1. Introduction

Colorectal cancer (CRC) is the third most common cancer worldwide, causing approximately 9.2% of cancer-related deaths [1,2]. Even after surgery, which represents the mainstay of treatment for early-stage of CRC, patients are often diagnosed with distant metastases. Currently, fluorouracil (5-FU) based systemic chemotherapy significantly improves the overall survival of advanced CRC patients. However, for those patients who have inherent resistance to chemotherapeutic agents, or acquired resistance with unknown mechanisms, chemotherapy still often fails [3–6]. Therefore, a better understanding of the mechanisms of colorectal tumorigenesis, or
Identification of pivotal targets toward the development of novel strategies with lower toxicity will have a high clinical impact. The F-box protein S-phase kinase-associated protein 2 (Skp2) is an essential subunit of the Skp1-Cullin-1-F-box (SCF) ubiquitin E3 ligase complex. Skp2 harbors the E3 ligase activity, which is required for substrate recognition of the SCF complex [7]. Previous studies have shown that Skp2 is overexpressed and positively correlated with poor prognosis in human malignancies, including colorectal cancer. The E3 ligase activity of Skp2 plays a crucial role in tumorigenesis via either inducing protein degradation through lysine 48 (K48)-linked polyubiquitination chains or activating signaling transduction by lysine 63 (K63)-linked polyubiquitination chains. Thus, Skp2 could be a potential drug target for human cancer therapy based on enzyme activity. Currently, the synthetic anti-cancer agents provide limited clinical benefits due to high toxicity and unwanted side effects. Natural products are a good source of compounds with unique chemical structures that are effective and less toxic. Therefore, targeting Skp2 by natural compounds is of great therapeutic significance in colorectal cancer.

2. Materials and methods

2.1. Reagents and antibodies

Chemical reagents, such as DMSO, NaCl, SDS, and Tris base for buffer preparation were obtained from Sigma-Aldrich (St. Louis, MO). The PBS, cell culture media, and antibiotics were purchased from Invitrogen (Grand Island, NY). Antibodies against Skp2 (#2652, IB: 1:2000, IHC: 1:100), HK1 (#2024, IB: 1:2000), HK2 (#2867, IB: 1:2000, IHC: 1:200), p-Akt (#4060, IB: 1:1000), Akt (#4691, IB: 1:2000), p-S6 (#4858, IB: 1:4000), p-Histone H3 (Ser10) (#53348, IF: 1:200), ubiquitin (#3936, IB: 1:1000), β-actin (#4970, IB: 1:5000), p27 (#3686, IB: 1:1000), anti-rabbit IgG HRP (#7074), and anti-mouse IgG HRP (#7076) were obtained from Cell Signaling Technology, Inc. (Beverly, MA). HK2 (LS-C404653) antibody for IHC staining was obtained from LifeSpan BioSciences, Inc. Antibodies against Ki67 (ab16667, IHC: 1:250) and donkey anti-rabbit IgG H&L (Alexa Fluor® 488) (ab150073, IF: 1:800) were purchased from Abcam (Cambridge, UK).

2.2. Cell lines and cell culture

Human colorectal cancer cell lines, including DLD1, HCT116, SW480, HT29, HCT8, and SW620 were purchased from the American Type Culture Collection (ATCC, Manassas, VA). Human normal colon epithelial cell FHC was obtained from ATCC. All cells were maintained at 37 °C in a humidified incubator with 5% CO2 according to the ATCC protocols. The cells were cytogenetically tested and authenticated before being frozen.

2.3. Protein preparation and western blotting

Whole cell extract (WCE) was prepared with RIPA buffer (20 mM NAP, pH 7.4, 150 mM NaCl, 0.5% Triton, 0.1% Sodium-deoxycholate, and 0.1% SDS) supplemented with protease inhibitors. BCA assay (#23228, Pierce, Rockford, IL) was used for protein concentration following the standard procedures. Western blotting was performed as previously described [18]. Brieﬂy, WCE was boilded with loading buffer at 95 °C for 5 min and subjected to SDS-PAGE followed by electrophoretic transfer to the PVDF membrane. The membrane was blocked with 5% non-fat milk and incubated with primary antibody at 4 °C overnight. Anti-rabbit IgG HRP and anti-mouse IgG HRP were used as secondary antibodies. The target protein was visualized using the ECL substrate (#32106, Thermo Fisher Scientific).

2.4. Immunofluorescence

Immunofluorescence was performed as previously described [19]. Brieﬂy, HT29 cells were seeded in chamber slides and treated with various concentrations of compound for 24 h. Cells were fixed in ice-cold methanol for 20 min at 4 °C. After a PBS wash, the fixed cells were incubated with 5% BSA at room temperature for 1 h and hybridized with p-Histone H3 Ser10 antibody in a humidified chamber overnight at 4 °C. Alexa Fluor 488 dye-labeled anti-rabbit IgG was used as the secondary antibody.

2.5. Immunohistochemical staining (IHC)

This study was approved by the Institute Research Ethics Committee of Xiangya Hospital, Central South University. Human colorectal cancer tissues and the paired adjacent tissues were obtained from the Departments of Pathology at Xiangya Hospital with written informed consent (n = 63). The tissues were fixed, embedded, and subjected to IHC analysis as described previously [20]. Brieﬂy, after incubating at 65 °C for 1 h, the tissue slides were submersed into sodium citrate buffer (10 mM, pH 6.0) and boiled for 10 min, followed by incubation in 3% H2O2 for 10 min. Tissue slides were blocked with

**Research in Context**

**Evidence before this study**

Colorectal cancer is the third most common cancer worldwide. Previous studies have shown that Skp2 is overexpressed and positively correlated with poor prognosis in human malignancies. Suppression of Skp2 reduced tumorigenic properties of various cancer cells, including colorectal cancer. The E3 ligase activity of Skp2 plays a crucial role in tumorigenesis via either inducing protein degradation through lysine 48 (K48)-linked polyubiquitination chains or activating signaling transduction by lysine 63 (K63)-linked polyubiquitination chains. Thus, Skp2 could be a potential drug target for human cancer therapy based on enzyme activity. Currently, the synthetic anti-cancer agents provide limited clinical benefits due to high toxicity and unwanted side effects. Natural products are a good source of compounds with unique chemical structures that are effective and less toxic. Therefore, targeting Skp2 by natural compounds is of great therapeutic significance in colorectal cancer.

**Added value of this study**

We demonstrated that Skp2 is highly expressed in CRC tissues and cell lines. Knockout of Skp2 inhibited HK2 and glycolysis, and decreased CRC cell growth in vitro and in vivo. By screening a natural product library through glycolysis analysis, we found that dioxin, a natural steroid saponin derived from several plants, inhibited glycolysis significantly in CRC cells. Dioxin decreased the protein level of Skp2 by shortening the half-life of Skp2. Further study showed that dioxin attenuated Skp2 phosphorylation on S72 and promoted the interaction between Skp2 and Cdh1, which eventually enhanced Skp2 lysine 48 (K48)-linked polyubiquitination and degradation. Depletion of Cdh1 impaired dioxin-induced Skp2 reduction, rescued HK2 expression, and glycolysis in CRC cells. Finally, dioxin delayed the in vivo tumor growth, promoted Skp2 ubiquitination, and inhibited Skp2 expression in a mouse xenograft model.

**Implications of all the available evidence**

The cumulative data suggest that in addition to pharmacological inactivation of Skp2, enhancement of ubiquitination-dependent Skp2 turnover is a promising approach for cancer treatment.
50% goat serum albumin at room temperature for 1 h and incubated with the primary antibody in a humidified chamber overnight in a cold room. Tissue slides were washed with PBS and hydrogenized with the secondary antibody at room temperature for 45 min. Hematoxylin was used for counterstaining.

2.6. MTS assays

Human colorectal cancer cells were seeded in 96-well plates (2 × 10³/well) and treated with different doses of compound or DMSO control. Cell viability was examined at various time points using the MTS reagent (G3581, Promega, Madison, WI).

2.7. 5-ethyl-2'-deoxyuridine (EdU) incorporation assay

The stable colorectal cancer cells were seeded into chamber slides at a density of 1 × 10⁵ cells and cultured overnight. Cells were then incubated with 10 μM of EdU (C10339, Thermo Fisher) and subjected to EdU incorporation analysis according to the manufacturer’s instructions.

2.8. Anchorage-independent cell growth assay

Colorectal cancer cells (8 × 10³ per well) were counted and seeded into 6-well plates with 0.3% Basal Medium Eagle agar containing 10% FBS and cultured. The cultures were maintained at 37 °C in a 5% CO₂ incubator for 2 weeks. Colonies were counted under a microscope, as previously described [21].

2.9. Natural compound screening

The Natural Product Library (Cat. No. L1400-01/02), which contains 88 compounds of interest, was a product of Selleck Chemicals (Houston, TX). HT29 cells were seeded in a 48-well plate and treated with a single dose of 2 μM natural products or DMSO (control) for 12 h. Cell culture medium was collected and subjected to glucose and lactate analysis at the Laboratory of Xiangya Hospital (Changsha, China). The relative glucose consumption and lactate production rate were normalized by protein concentration. Tested compounds are listed in Table S1.

2.10. Transient transfection and generation of silencing stable cell lines

Lipofectamine 2000 (#11668–019, Invitrogen, Carlsbad, CA) was used for transient transfection according to the instructions provided. Two different single-guide RNAs (sgRNAs) were used to generate CRISPR-Cas9-based Skp2 knockout constructs (sgSkp2#1 forward, 5'-AGAAGCTTTGATTCGATAGGTCCATGTGCTG-3', reverse, 5'-GGGCATCGACCAACTCA-3'), (sgSkp2#2 forward, 5'-GACCTGAGTAGAAGACTTTGTGATTGTCCGC-3', reverse, 5'-CGGGCAATACACAAACTCTTT-3'), sgSkp2#2 forward, 5'-GACCTGAGTAGAAGACTTTGTGATTGTCCGC-3', reverse, 5'-CGGGCAATACACAAACTCTTT-3'). The Skp2 stable knockout signal clone was generated by transient transfection of sgSkp2 plasmids followed by selection with 1 μg/mL puromycin for 3 weeks. The Cdh1 siRNA (Cat. A-003877–17–0005) and shRNA (Cat. V3SH11240–228718527) were purchased from GE Horizon Discovery. Lentivirus-mediated Cdh1 knockdown stable cell line was performed as described previously [22]. Briefly, the shCdh1 lentivirus plasmid, psiPAX2, and pMD2.G were co-transfected into 293T cells. The virus-containing supernatant was collected and filtered through a 0.45 μm filter at 48 h after transfection and infected with CRC cells together with 6 μg/mL polybrene. Cells were selected by 1 μg/mL puromycin for 3 days. The primer for Skp2 qRT-PCR analysis is forward sequence: GAGTTCGATAGGTCCATGTGCTG, reverse sequence: GAGTTCGATAGGTCCATGTGCTG.

2.11. Glucose uptake and lactate production

Glycolysis measurement was performed, as described previously [23]. Briefly, colorectal cancer cells were seeded in 6-well plates (5 × 10⁴) and maintained in the incubator overnight. The cells were treated with different doses of dioscin or DMSO control for 10 h. The cell culture medium was harvested and subjected to glycolysis analysis. Glucose and lactate levels were measured (Automatic Biochemical Analyzer; 7170A, HITACHI, Tokyo, Japan) at the Laboratory of Xiangya Hospital (Changsha, China). Protein concentration was determined by BCA protein assay to normalize the relative glucose consumption and lactate production rate.

2.12. Ubiquitination analysis

Ubiquitination analysis was performed, as described previously [17]. Briefly, cell lysates were prepared using the modified RIPA buffer (20 mM NAP, pH 7.4, 150 mM NaCl, 1% Triton, 0.5% Sodium-deoxycholate, and 1% SDS) supplied with 10 mM N-Ethylmaleimide (NEM) and protease inhibitors. After sonication for 30 s, the supernatant was boiled at 95 °C for 15 min, followed by diluted with RIPA buffer containing 0.1% SDS and centrifuged at 16,000 × g for 15 min at 4 °C. The supernatant was incubated with anti-Skp2 antibody and 30 μL protein A-Sepharose beads overnight in a cold room. After extensive washing and centrifuge, the binding proteins were eluted by boiling with 2 × SDS sample loading buffer at 95 °C for 5 min. Skp2 ubiquitination was determined by western blotting analysis.

2.13. In vivo tumor growth assay

The in vivo animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of Xiangya Hospital, Central South University (Changsha, China). The xenograft mouse model was generated by s.c. injection of colorectal cancer cells (2 × 10⁶) into the right flank of 6-week-old athymic nude mice (n = 6). Tumor size was measured with calipers every two days. For compound treatment, mice were administrated with dioscin (10 mg/kg every two days) by i.p. injection when the tumor volume reached around 100 mm³, while the control group was administrated with the vehicle. Tumor volume was measured with calipers every two days and determined according to the following formula: length × width × width/2.

2.14. Statistical analysis

Statistical analyses were performed using GraphPad Prism 5 (GraphPad 5.0, San Diego, CA, USA). The quantitative data are expressed as mean ± sd, the difference was evaluated using the Student's t-test or ANOVA. A probability value of p < 0.05 was used as the criterion for statistical significance.

3. Results

3.1. Skp2 is required for the maintenance of tumorigenic properties in human colorectal cancer cells

To determine the role of Skp2 in human colorectal cancer (CRC), immunohistochemical (IHC) staining was performed to examine the protein level of Skp2 in colorectal cancer tissues. As shown in Fig. 1a, Skp2 was upregulated in CRC tissues as compared to the paired adjacent tissues. The immunoblotting (IB) data indicated that Skp2 was highly expressed in human CRC cell lines, whereas the normal colon epithelial cell FHC exhibited a lower protein level by comparison (Fig. 1b). Based on these observations, we hypothesized that Skp2 might affect the
tumorigenic properties in CRC. Thus, we constructed Skp2 stable knockout HCT116 and HT29 cells. MTS results showed that depletion of Skp2 significantly decreased cell viability in both SW620 and HT29 cells (Fig. 1c). The EdU incorporation assay further demonstrated that knockout of Skp2 reduced cell proliferation in HT29 cells (Fig. 1d). Furthermore, the efficacy of colony formation in soft agar was attenuated significantly in Skp2 deficient cells as expected (Fig. 1e). To determine the role of Skp2 in the tumorigenesis of CRC in vivo, we constructed a xenograft mouse model using SW620-sgCtrl and SW620-sgSkp2 stable cells. Our data showed that depletion of Skp2 delayed in vivo tumor development significantly (Fig. 1f–h). These results suggest that blocking Skp2 expression reduces the tumorigenic properties of CRC cells.

3.2. Skp2 is required for aerobic glycolysis in CRC cells

As cell culture media of sgCtrl cells turned yellow much faster than that of sgSkp2 stable cells, we hypothesized that this phenotype might be due to lactate acidosis. Indeed, depletion of Skp2 in HT29 cells impaired the capability to decrease medium pH values in sgCtrl cells (Fig. 2a). Moreover, glucose consumption and lactate production were significantly reduced in Skp2 deficient HT29 cells (Fig. 2b and 2c). Because these metabolic changes resembled aerobic glycolysis, we further identified that Hexokinase 2 (HK2), but not HK1, was markedly decreased in Skp2 stable knockout cells (Fig. 2d). Consistently, ectopic overexpression of Skp2 promoted HK2 protein level, glucose consumption, and lactate production (Fig. 2e–g) in FHC epithelial cells. We then restored HK2 expression in Skp2 deficient HT29...
cells to investigate whether it was required for Skp2-mediated aerobic glycolysis. Overexpression of HK2 rescued glucose consumption and lactate production in sgSkp2 stable cells (Fig. 2h–j). Skp2 is reportedly required for Akt K63-linked ubiquitination and activation, and the upregulation of Akt signaling promotes HK2 expression and glycolysis. Thus, we examined whether the decrease of HK2 in Skp2 knockout cells is related to Akt deactivation. The IB results showed that depletion of Skp2 impaired the phosphorylation of Akt and downstream kinase S6 in HT29 cells (Fig. 2k). In contrast, overexpression of Skp2 promoted the activation of Akt and S6 in FHC cells (Fig. 2l). Moreover, constitutively activated Akt1 (Myr-Akt1) upregulated HK2 protein level and rescued glucose consumption and lactate production in Skp2 stable knockout HT29 cells (Fig. 2m–o). These results indicate that Skp2-mediated glycolysis in CRC cells is partly dependent on the Skp2-Akt-HK2 axis.

3.3. Dioscin inhibits glycolysis in CRC cells

To discover natural compounds (Table S1) that can specifically suppress Skp2 signaling and glycolysis, we screened a library of 88 natural products that inhibit glucose consumption and lactate production of CRC cells. The results showed that only dioscin decreased both glucose consumption and lactate production by over 30% at the concentration of 2 μM (Fig. 3a–c) on HT29 cells.
Therefore, dioscin is our focus for further study. To validate the inhibitory effect of dioscin, we treated CRC cells at various concentrations. As Fig. 3d demonstrated, dioscin suppressed cell viability in a dose- and time-dependent manner. Moreover, the IB results indicated that dioscin decreased the protein level of Skp2, p-Akt, and HK2 in HCT116, HT29, and SW620 cells (Fig. 3e), suggesting that dioscin might be an inhibitor of Skp2 signaling. Furthermore, dioscin impaired glycolysis dose-dependently, because the glucose uptake and lactate production efficacy were attenuated significantly after dioscin treatment (Fig. 3f and g). Aerobic glycolysis is required for maintaining cancer cell growth, so we examined the effect of dioscin on phosphorylation of Histone H3 Ser10, a marker of cell proliferation. The immunofluorescence (IF) results showed that dioscin inhibited the phosphorylation of Histone H3 Ser10 significantly (Fig. 3h), which is consistent with the MTS data and further confirms that dioscin exhibits an anti-tumor effect on CRC cells.

**Fig. 3.** Dioscin suppresses Skp2 and glycolysis in CRC cells. (a) Schematic workflow of the natural compound screening. (b and c) The inhibitory efficacy of screened compounds on glucose consumption (b) and lactate production (c) of HT29 cells. (d and e) HCT116 (left), HT29 (middle), and SW620 cells (right) were treated with DMSO or dioscin and subjected to MTS assay (d) or IB analysis (e). ***p < 0.001. (f and g) CRC cells were treated with DMSO or dioscin and subjected to glucose consumption (f) and lactate production (g) analysis. *p < 0.05, **p < 0.01, ***p < 0.001. (h) HT29 cells were treated with DMSO or dioscin and subjected to immunofluorescence analysis with a p-H3 S10 antibody. **p < 0.01, ***p < 0.001.
3.4. Dioscin promotes Skp2 ubiquitination and degradation

Because dioscin decreased Skp2 protein levels and glycolysis dose-dependently (Fig. 3e), we first characterize the mechanism that regulates Skp2 turnover. Dioscin shortened the half-life of endogenous Skp2 from 4 h to 1 h in the presence of cycloheximide (CHX) (Fig. 4a), whereas the mRNA had no significant difference (Fig. S1), suggesting that exposure to dioscin caused protein instability. Indeed, treatment with proteasome inhibitor, MG132, rescued dioscin-induced reduction of Skp2 in CRC cells (Fig. 4b), which further implied that dioscin promoted Skp2 degradation. To determine whether Skp2 destruction in CRC cells is increased upon dioscin treatment, we determined endogenous Skp2 poly-ubiquitination in vivo. As shown in Fig. 4c, dioscin enhanced Skp2 poly-ubiquitination markedly in HT29 cells. Moreover, using the ubiquitin mutants, HA-Ub K48 (lysine 48 only) and HA-Ub K63 (lysine 63 only), we demonstrated that dioscin-induced Skp2 ubiquitination was K48-linked (Fig. 4d). To examine the relationship between Skp2 activity and destruction, we further determined the protein level of p27, the downstream target of E3 ligase Skp2. The IB results showed that dioscin promoted p27 protein level dose-dependently (Fig. 4e) in HCT116, HT29, and SW620 cells. These results indicate that dioscin decreases Skp2 protein levels in a ubiquitination-dependent manner.

3.5. Cdh1 is required for dioscin-induced Skp2 destruction in CRC cells

The tumor suppressor APC/C\(^{\text{Cdh1}}\) plays a crucial role in the regulation of Skp2 stability [24,25]. We determined whether Cdh1 is required for dioscin-induced Skp2 degradation in CRC cells. The endogenous binding between Skp2 and Cdh1 was identified via reciprocal co-immunoprecipitation (co-IP) in HT29 cells. Moreover, this interaction was enhanced by dioscin treatment (Fig. 5a). Dioscin promoted Skp2 ubiquitination in siCtrl transfected cells, whereas knockdown of Cdh1 impaired dioscin-induced Skp2 ubiquitination (Fig. 5b). Moreover, overexpression of Cdh1 in Cdh1 knockdown cells restored dioscin-induced Skp2 ubiquitination (Fig. 5c), indicating that Cdh1 is required for dioscin-induced Skp2 destruction. Stable knockdown of Cdh1 in HT29 cells increased Skp2 and HK2 protein level and compromised dioscin-induced reduction of Skp2 and HK2 (Fig. 5d). The efficacy of dioscin-mediated glycolysis suppression was attenuated significantly in Cdh1 deficient cells (Fig. 5e and f). Previous studies show that phosphorylation of S72 promotes Skp2 stability and suppresses the proteasome-mediated degradation [26,27]. The IB data showed that treatment with dioscin decreased Skp2 Ser/Thr-phosphorylation (Fig. 5g). To validate whether S72 is phosphorylated, we constructed the S72A (Ser-to Ala) mutant and found that Skp2 Ser/Thr-phosphorylation was markedly decreased (Fig. 5h), which suggests that Skp2 S72 is one of the primary phosphorylation sites in CRC cells. To determine whether Skp2 S72 phosphorylation is required for maintaining protein stability, we compared the poly-ubiquitination of Skp2 S72A with Skp2 WT. The in vivo ubiquitination assay showed that dioscin-induced Skp2 ubiquitination was enhanced in the Skp2 S72A mutant (Fig. 5i). To determine whether dioscin decreased Skp2 Ser/Thr-phosphorylation is dependent on Akt signaling, we ectopically overexpressed constitutively active Akt1, HA-Myr-Akt1, in CRC cells. The data showed that overexpression of Akt1 compromised dioscin-induced Skp2 Ser/Thr-phosphorylation suppression (Fig. 5j). Furthermore, overexpression Akt1 promoted phosphorylation of WT Skp2, but not that of the Skp2 S72A mutant (Fig. 5k). These results indicated that Akt promoted Skp2 phosphorylation on S72, and this residue was one of the major phosphorylation sites which was inhibited by dioscin and rescued by Akt kinase. In addition, the interaction between Akt and Skp2 was unaffected by dioscin treatment (Fig. 5l), indicating that the decrease of Skp2 phosphorylation on S72 was not caused by attenuation of interaction. Collectively, our data suggest that the suppression of Skp2 phosphorylation is required for Cdh1-mediated Skp2 destruction in dioscin-treated CRC cells.

3.6. Dioscin inhibits tumor growth in vivo

We next determined the anti-tumor effect of dioscin using an in vivo nude mouse model. HT29 and SW620 cells were injected (s.c.) into the right flank of female athymic nude mice. After the tumor volume reached around 100 mm\(^3\), the tumor-bearing mice were treated with dioscin or vehicle control. The results showed that in the HT29 xenograft model, the average tumor size of the vehicle-
treated group reached 867 ± 143 mm³, whereas the dioscin-treated group was only 297 ± 51 mm³ (Fig. 6a). Dioscin exhibited a similar inhibitory efficacy on SW620 xenograft tumors, as the tumor volume of the vehicle- and dioscin-treated groups were 659 ± 113 mm³ and 194 ± 53 mm³, respectively (Fig. 6d). Moreover, the average tumor weight of both HT29 (Fig. 6b and c) and SW620 (Fig. 6e and f) xenograft tumors with dioscin treatment was significantly reduced compared to that of the vehicle-treated groups. Mice tolerated the treatment with dioscin well without noticeable body weight loss (Fig. S3a and S3b). The immunohistochemical staining (IHC) results showed that dioscin-treated HT29 and SW620 xenograft tumors exhibited significant attenuation of Ki67 expression, correlated with the reduction of Skp2 and HK2 protein level (Fig. 6g, Fig. S3c). We next determined whether Skp2 ubiquitination is upregulated in compound-treated xenograft tumors. Indeed, the ubiquitination of Skp2 was higher in dioscin-treated tumors than that in vehicle-treated tumors (Fig. 6h, Fig. S3d). These findings indicate that dioscin inhibits CRC tumor growth in vivo. This may occur through the induction of Skp2 ubiquitination and suppression of HK2 in tumor tissues.

**Fig. 5.** Cdh1 is required for dioscin-induced Skp2 ubiquitination. (a) HT29 cells were treated with dioscin for 24 h, WCE was subjected to co-immunoprecipitation (co-IP) analysis. (b) HT29 cells were transfected with siCtrl or siCdh1 and treated with DMSO or dioscin for 24 h, followed by MG132 treatment for another 6 h. WCE was collected and subjected to in vivo ubiquitination assay. (c) HT29 cells were transfected with siCtrl or siCdh1 for 24 h. The siCdh1 transfected cells were overexpressed with Cdh1 and treated with DMSO or dioscin for 24 h, followed by MG132 treatment for another 6 h. WCE was subjected to in vivo ubiquitination assay. (d–f) HT29 cells were transfected with Flag-Skp2 WT and Flag-Skp2 (S72A) mutant for 48 h, WCE was subjected to co-IP assay followed by IB analysis. (g) HT29 cells were transfected with the constructs as indicated for 24 h, cells were then treated with DMSO or dioscin for 24 h, followed by MG132 treatment for 6 h, WCE was subjected to in vivo ubiquitination assay.

---

**Fig. 6.** (a) HT29 cells were treated with dioscin for 24 h, WCE was subjected to co-immunoprecipitation (co-IP) analysis. (b) HT29 cells were transfected with siCtrl or siCdh1 and treated with DMSO or dioscin for 24 h, followed by MG132 treatment for another 6 h. WCE was collected and subjected to in vivo ubiquitination assay. (c) HT29 cells were transfected with siCtrl or siCdh1 for 24 h. The siCdh1 transfected cells were overexpressed with Cdh1 and treated with DMSO or dioscin for 24 h, followed by MG132 treatment for another 6 h. WCE was subjected to in vivo ubiquitination assay. (d–f) HT29 cells were transfected with Flag-Skp2 WT and Flag-Skp2 (S72A) mutant for 48 h, WCE was subjected to co-IP assay followed by IB analysis. (g) HT29 cells were transfected with the constructs as indicated for 24 h, cells were then treated with DMSO or dioscin for 24 h, followed by MG132 treatment for 6 h, WCE was subjected to in vivo ubiquitination assay.

---

**Fig. S3.** (a) HT29 cells were treated with dioscin for 24 h, WCE was subjected to co-immunoprecipitation (co-IP) analysis. (b) HT29 cells were transfected with siCtrl or siCdh1 and treated with DMSO or dioscin for 24 h, followed by MG132 treatment for another 6 h. WCE was collected and subjected to in vivo ubiquitination assay. (c) HT29 cells were transfected with siCtrl or siCdh1 for 24 h. The siCdh1 transfected cells were overexpressed with Cdh1 and treated with DMSO or dioscin for 24 h, followed by MG132 treatment for another 6 h. WCE was subjected to in vivo ubiquitination assay. (d–f) HT29 cells were transfected with Flag-Skp2 WT and Flag-Skp2 (S72A) mutant for 48 h, WCE was subjected to co-IP assay followed by IB analysis. (g) HT29 cells were transfected with the constructs as indicated for 24 h, cells were then treated with DMSO or dioscin for 24 h, followed by MG132 treatment for 6 h, WCE was subjected to in vivo ubiquitination assay.
4. Discussion

Overexpression of Skp2 is frequently observed in human malignancies [28]. Although p27 is a critical substrate of Skp2, many additional targets of Skp2 have been identified, including Akt [8], LKB1 [29], NBS1 [30], amongst others. The E3 ligase activity of Skp2 plays a crucial role in tumorigenesis via either induced protein degradation through lysine 48 (K48)-linked polyubiquitination chain or activating signaling transduction by lysine 63 (K63)-linked polyubiquitination chain. Thus, Skp2 could be a potential drug target for human cancer therapy based on enzyme activity. Early studies show that Skp2 is required for tumorigenesis in mouse models in the context of BCR-ABL overexpression [31], p53/PTEN-deficient [32], or pRB inactivation [33]. Pharmacological inactivation of Skp2 ubiquitin ligase by small-molecules restricts cancer stem cell traits and cancer progression in multiple cancer models [34–36]. In this study, we identify that the natural compound dioscin suppresses Skp2 expression via the promotion of Skp2 ubiquitination and degradation in a Cdh1 dependent manner. Dioscin decreased Skp2 protein level and reduced glycolysis in CRC cells both in vitro and in vivo. Moreover, several natural compounds such as curcumin [37–39], saurolactam [40], rottlerin [41], and Longikaurin A [42] have been reported to inhibit the expression of Skp2 and decrease the malignant phenotype of human cancer cells. These results support the notion that Skp2 is a promising drug target for human cancers.

Currently, synthetic anti-cancer agents only provide limited clinical benefits due to high toxicity and unwanted side effects. Natural products are a good source of compounds with unique chemical structures that are effective and less toxic. Dioscin, a natural steroid saponin derived from several plants, exhibits significant anti-tumor activity towards several types of cancer, including lung [43], prostate [44], breast [45], liver [46], and colorectal [47] cancer. Attenuation of kinase activity, inhibition of angiogenesis and metastasis, suppression of transcription factor activity, and induction of apoptosis were demonstrated to be the underlying mechanisms of dioscin-mediated anti-tumor activity [48]. However, very little is known about the effects of dioscin on the regulation of glycolysis in human CRC cells. In this study, we identify that dioscin exhibits a strong inhibitory effect on glucose consumption and lactate production using natural compound screening in CRC cells. We unexpectedly find that this process is dependent on dioscin-induced Skp2 ubiquitination and degradation. Early reports demonstrate that the regulation of Skp2 turnover is mediated by the anaphase-promoting complex (APC), in association with its substrate-specific factor Cdh1 [24,25]. Moreover, mutation or dysfunction of Cdh1 is implicated in the tumorigenesis of human CRC [49,50]. Our data show that dioscin suppresses Skp2 phosphorylation on S72 and promotes the interaction between Skp2 and
Cd1, thus enhancing Cd1-mediated Skp2 destruction, and eventually decreasing HK2 protein level and glycolysis in CRC cells. Accumulating evidence indicates that Skp2 plays a critical role in CRC development. Amplification or higher copy numbers of Skp2 is associated with increased CRC risk [51]. G9a-mediated methylation promotes Skp2-mediated FOXO1 degradation and cell proliferation in CRC [52]. Combined Menin and EGFR inhibitors synergize to inhibit CRC via EGFR-independent and calcium-mediated repression of Skp2 transcription [53]. Moreover, NDRG2 inhibits Skp2 and results in the induction and stabilization of p21 and p27, which facilitates CRC differentiation [54]. Additionally, bortezomib suppresses CRC through the promotion of Skp2 degradation in CRC cells [55]. Our data show that Skp2 is required for the maintenance of CRC cell growth both in vitro and in vivo. Depletion of Skp2 decreases cell viability, proliferation, colony formation, and in vivo tumor formation of CRC cells. Furthermore, we demonstrate that Skp2 promotes glycolysis in CRC cells via upregulation of HK2 protein level. Ectopic overexpression of HK2 rescued Skp2 deficiency-induced glycolysis suppression. Although the glucose uptake of mammalian cells is controlled by the glucose transporter, Gluts [56], reduction of HK2 protein level might impair the glucose metabolism in mitochondria, which eventually decreases the glucose uptake rate due to the accumulation of glucose in cells. Also, HK2 mitochondrial localization is regulated by Akt signaling [17,57]. Knockout of Skp2 might suppress Akt activity, which in turn increases the cytosolic distribution of HK2 and reduces the mitochondrial associated HK2 simultaneously. Moreover, the accumulation of glucose-6-phosphate (G6P) in mitochondria might lead to negative regulation of HK2 kinase activity through a negative feedback mechanism [58,59], which might cause the downregulation total quantity of HK2 in mitochondria. Thus, restoration of HK2 in Skp2 knockout cells rescued glycolysis. Lin et al. have demonstrated that Skp2 is required for aerobic glycolysis in breast cancer by the promotion of Glut1 expression. Skp2-induced K63-Linked Akt ubiquitination and conferred herceptin resistance [8]. Our data show that knockout of Skp2 decreases Akt signaling, and transfection of Myr-Akt1 restores HK2 expression and glycolysis in CRC cells, indicating that Akt activity is also required for Skp2-mediated HK2 and glycolysis regulation. In summary, we demonstrate that Skp2 promotes HK2 expression and glycolysis, and knockout of Skp2 reduces tumorigenic properties of human CRC cells. We identify that dicosin inhibits Skp2 S72 phosphorylation and eventually enhances Skp2 ubiquitination and degradation in a Cdh1 dependent manner. Beyond pharmacological inactivation of Skp2 E3 ligase activity, our discovery reveals that the suppression of Skp2 protein levels, by the inducement of ubiquitination and degradation, is a compelling therapeutic strategy that deserves further study for cancer prevention and treatment.

**Declaration of Competing Interest**

The authors have declared no conflicts of interest.

**Acknowledgments**

The authors are grateful to John Angles and Shiyu Chen at The State University of New York, for editing the manuscript and providing critical comments.

**Supplementary materials**

Supplementary material associated with this article can be found in the online version at doi:10.1016/j.ebiom.2019.11.031.

**References**

[1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424.
[2] Kreun N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol 2019.
[3] Nagtegaal ID, Knijn N, Hugen N, Marshall HC, Sugihara K, Tot T, et al. Tumor deposits in colorectal cancer: improving the value of modern Staging-A system: a systematic review and meta-analysis. J Clin Oncol 2017;35(10):1119–27.
[4] Petroilli F, Zaniboni A, Ghidini A, Ghidini M, Turati L, Pizzo C, et al. Timing of adjuvant chemotherapy and survival in colorectal, gastric, and pancreatic cancer: a systematic review and meta-analysis. Cancers (Basel) 2019;11(4).
[5] Feng W, To KK W. Drug repurposing to overcome resistance to various therapies for colorectal cancer. Cell Mol Life Sci 2019;76(17):3383–406.
[6] Szczepańska A, Picchina J. Organometallic compounds and metal complexes in current and future treatments of inflammatory bowel disease and colorectal cancer—a critical review. Bioinnovations 2019;9(9).
[7] Zheng N, Zhou Q, Wang Z, Wei W. Recent advances in SCF ubiquitin ligase complex: clinical implications. Biochem Biophys Acta 2016;1866(1):12–22.
[8] Chan CH, Li CF, Yang WL, Gao Y, Lee SW, Feng Z, et al. The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell 2012;149(5):1098–1111.
[9] Yang G, Ayala G, De Marzo A, Tian W, Frolow A, Wheeler TM, et al. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res 2008;14(11):3419–26.
[10] Wang J, Huang Y, Guan Z, Zhang JL, Su HK, Zhang W, et al. E3-ligase Skp2 predicts poor prognosis and maintains cancer stem cell pool in nasopharyngeal carcinoma. Oncotarget 2014;5(14):5591–601.
[11] Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H, p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol 1999;9(12):661–4.
[12] Yu ZK, Gervas JS, Zhang H. Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1)/WAF1 and cyclin D proteins. Proc Natl Acad Sci U S A 1998;95(19):11324–9.
[13] Li X, Zhao T, Hara T, Kotorita S, Yada M, Ishida N, et al. Degradation of p57Kip2 mediated by SKP2/Skp2-dependent ubiquitilation. Proc Natl Acad Sci U S A 2003;100(18):10231–6.
[14] Wang Z, Fukushima H, Inuzuka H, Wan L, Liu P, Gao D, et al. Skp2 is a promising therapeutic target in breast cancer. Front Oncol 2012;2(57).
[15] Hao Z, Huang S, E3 ubiquitin ligase Skp2 as an attractive target in cancer therapy. Front Biosci (Landmark Ed) 2015;20:474–90.
[16] Su KJ, Yu YL. Downregulation of SHIP2 by hepatitis B virus X promotes the metastasis and chemoresistance of hepatocellular carcinoma through SKP2. Cancers (Basel) 2019;11(8).
[17] Yu X, Wang R, Zhang Y, Zhou L, Wang W, Liu H, et al. Skp2-mediated ubiquitination and mitochondrial localization of Akt drive tumor growth and chemoresistance of hepatocellular carcinoma. Cancers 2017;8(20):32586–90.
[18] Zhou L, Li M, Yu X, Gao F, Li F, et al. Repression of hexokinases II-mediated glycolysis contributes to piperlongumine-induced tumor suppression in non-small cell lung cancer cells. Int J Biol Sci 2019;15(4):826–37.
[19] Yu X, Liang Q, Liu W, Zhou L, Li W, Liu H, Deguelin, an aurora B kinase inhibitor, exhibits potent anti-tumor effect in human esophageal squamous cell carcinoma. EBioMedicine 2017;26:100–11.
[20] Liu H, Li W, Yu X, Gao F, Duan Z, Ma X, et al. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis. Oncotarget 2016;7(35):56338–54.
[21] Li W, Yu X, Xia Z, Yu X, Xie L, Ma X, et al. Repression of Noxa by Bmi1 contributes to deguelin-induced apoptosis in non-small cell lung cancer cells. J Cell Mol Med 2018;22(12):6213–27.
[22] Yu X, Li W, Xia Z, Xie L, Ma X, Liang Q, et al. Targeting MCL-1 sensitizes human esophageal squamous carcinoma cells to cisplatin-induced apoptosis. BMC Cancer 2017;17(1):449.
[23] Li W, Gao F, Ma X, Wang R, Dong X, Wang W. Deguelin inhibits non-small cell lung cancer via down-regulating hexokinases II-mediated glycolysis. Oncotarget 2017;8(20):32586–99.
[24] Wei W, Ayala NG, NC, Wan Y, Zhang GJ, Kirschner MW, Kaelin Jr. The therapeutic target in breast cancer. Front Oncol 2012;2(57).
[25] Bashir T, Dorrello NV, Amador V, Guardavaccaro D, Pagano M. Control of the SCF ubiquitin ligase complex. Nature 2004;428(6979):194–26.
[26] Lin HK, Wang G, Chen Z, Teruya-Feldstein J, Liu Y, Chan CH, et al. Phosphorylation of Skp2 by Akt/PKB. Nat Cell Biol 2009;11(4):420–6.
[27] Bashir T, Dorrello NV, Amador V, Guardavaccaro D, Pagano M. Control of the SCF ubiquitin ligase complex. Nature 2004;428(6979):194–26.
[28] Bashir T, Dorrello NV, Amador V, Guardavaccaro D, Pagano M. Control of the SCF ubiquitin ligase complex. Nature 2004;428(6979):194–26.
[29] Bashir T, Dorrello NV, Amador V, Guardavaccaro D, Pagano M. Control of the SCF ubiquitin ligase complex. Nature 2004;428(6979):194–26.
Wang Y, Zhang T, Zhang S, Shan J. Prognostic values of F-box members in breast cancer: an online database analysis and literature review. Biosci Rep 2019;39(1).

Lee SW, Li CF, Jin G, Cai Z, Han F, Chan CH, et al. Skp2-dependent ubiquitination and activation of LKB1 is essential for cancer cell survival under energy stress. Mol Cell 2015;57(6):1022–33.

Wu J, Zhang X, Zhang L, Wu CY, Rezaeean AH, Chan CH, et al. Skp2 E3 ligase integrates ATM activation and homologous recombination repair by ubiquitinating NBS1. Mol Cell 2012;46(3):351–61.

Agarwal A, Bumm TG, Corbin AS, O'Hare T, Loriaux M, VanDyke J, et al. Absence of Skp2 expression attenuates BCR-ABL-induced myeloproliferative disease. Blood 2008;112(5):1960–70.

Lin HK, Chen Z, Liu H, Li B, Zhang Y, Piao C. Saurolactam inhibits proliferation, migration, and invasion of human osteosarcoma cells. Cell Biochem Biophys 2015;72(3):719–29.

Su J, Zhou X, Wang L, Yin X, Wang Z. Curcumin inhibits cell growth and invasion through activation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell 2013;154(3):556–68.

Chen Q, Xie W, Kuhn DJ, Voorhees PM, Lopez-Girona A, Mendy D, et al. Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood 2008;111(9):4690–9.

Sosac Y, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009;458(7239):732–6.

Khan AQ, Siveen KS, Prabhu KS, Kuttikrishnan S, Akhtar S, Shaar A, et al. Curcumin-Mediated degradation of S-Phase kinase protein 2 induces cytotoxic effects in human papillomavirus-positive and negative squamous carcinoma cells. Front Oncol 2018;8:399.

Su J, Zhou X, Wang L, Yin X, Wang Z. Curcumin inhibits cell growth and invasion and induces apoptosis through down-regulation of Skp2 in pancreatic cancer cells. Am J Cancer Res 2016;6(9):1949–62.

Feng S, Wang Y, Zhang R, Yang G, Liang Z, Wang Z, et al. Curcumin exerts its anti-tumor activity through regulation of miR-7/Skp2/p21 in nasopharyngeal carcinoma cells. Onco Targets Ther 2017;10:2377–88.

Li Z, Liu H, Li B, Zhang Y, Piao C. Saurolaetam inhibits proliferation, migration, and invasion of human osteosarcoma cells. Cell Biochem Biophys 2015;72(3):719–26.

Su J, Wang L, Yin X, Zhao Z, Hou Y, Ye X, et al. Rottlerin exhibits anti-cancer effect through inactivation of S phase kinase-associated protein 2 in pancreatic cancer cells. Am J Cancer Res 2016;6:10:2178–91.

Liao YJ, Bai HY, Li ZH, Zou J, Chen JW, Zheng F, et al. Longikaurin A, a natural ent-kaurane, induces G2/M phase arrest via downregulation of Skp2 and apoptosis induction through ROS/JNK/c-Jun pathway in hepatocellular carcinoma cells. Cell Death Dis 2014;5:e1137.

Wang Y, Fu M, Liu J, Yang J, Yu Y, Li J, et al. Inhibition of tumor metastasis by targetted daunorubicin and dioscin codeelivery liposomes modified with PIV for the treatment of non-small-cell lung cancer. Int J Nanomedicine 2019;14:4071–90.

Tao X, Xu L, Yin L, Han X, Q J, Y, Xu Y, et al. Dioscin induces prostate cancer cell apoptosis through activation of estrogen receptor-beta. Cell Death Dis 2017;8(8):e2989.

Wang C, Hsu W, Wang L, Meng Q, Liu Z, Liu Q, et al. Dioscin strengthens the efficiency of adriamycin in MCF-7 and MCF-7/ADR cells through autophagy induction: more than just down-regulation of MDR1. Sci Rep 2016;6:26403.

Mao Z, Han X, Chen D, Xu Y, Xu L, Yin L, et al. Potent effects of dioscin against hepatocellular carcinoma through regulating TP53-induced glycolysis and apoptosis regulator (TIGAR)-mediated apoptosis, autophagy, and DNA damage. Br J Pharmacol 2019;176(7):919–37.

Li S, Cheng B, Hou L, Huang L, Cui Y, Xu D, et al. Dioscin inhibits colon cancer cells’ growth by reactive oxygen species-mediated mitochondrial dysfunction and p38 and JNK pathways. Anticancer Drugs 2018;29(3):234–42.

Tao X, Yin L, Xu L, Peng J. Dioscin: a diverse acting natural compound with therapeutic potential in metabolic diseases, cancer, inflammation and infections. Pharmacol Res 2018;137:259–65.

Richards FM, McKee SA, Rajpar MH, Cole TR, Evans DG, Jankowski JA, et al. Germ-line E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum Mol Genet 1999;8(4):607–10.

Ow SGW, Tan KT, Yang H, Yap HL, Sapari NSB, Ong PY, et al. Next generation sequencing reveals novel mutations in mismatch repair genes and other cancer predisposition genes in asian patients with suspected Lynch syndrome. Clin Colorectal Cancer 2019.

Bi H, Liu Y, Tian T, Xia T, Pu R, Zhang Y, et al. A propensity score-adjusted analysis of the effects of ubiquitin E3 ligase copy number variation in peripheral blood leukocytes on colorectal cancer risk. J Cancer 2019;10(14):3291–302.

Chae YC, Kim JY, Park JW, Kim KB, Oh H, Lee KH, et al. FOXO1 degradation via C9a-mediated methylation promotes cell proliferation in colon cancer. Nucleic Acids Res 2019;47(4):1692–705.

Katona BW, Glynn RA, Paulesky KE, Feng Z, Davis C, Ma J, et al. Combined Menin and EGFRI inhibitors synergize to suppress colorectal cancer via EGRF-Independent and calcium-mediated repression of SKP2 transcription. Cancer Res 2019;79(9):2195–207.

Shen L, Qu X, Li H, Xu C, Wei M, Wang Q, et al. NDRG2 facilitates colorectal cancer differentiation through the regulation of Skp2/p21/p27 axis. Oncogene 2018;37(13):1759–74.

Uddin S, Ahmed M, Ravi P, El-Sayed R, Al-Sanea N, Abduljabbar A, et al. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer. Cancer Res 2008;68(9):3739–88.

Adekola K, Rosen ST, Shanmugam M. Glucose transporters in cancer metabolism. Curr Opin Oncol 2012;24(6):650–4.

Roberts DJ, Tan-Sah VP, Smith JM, Miyamoto S. Akt phosphorylates HK-II at Thr-473 and increases mitochondrial HK-II association to protect cardiomyocytes. J Biol Chem 2013;288(33):23798–806.

Pederse PL, Mathuska S, Rempel A, Geschwindt JF, Ko YH. Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim Biophys Acta 2002;1559(1–3):14–20.

Tan VP, Miyamoto S. HK2/hexokinase-II integrates glycolysis and autophagy to confer cellular protection. Autophagy 2015;11(6):563–4.